Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)

• Status: Completed
• Trial end date: 2012-12-01

Summary

To evaluate the management of HIV-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of France.

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: HIV Integrase Inhibitors; Integrase Inhibitors; Raltegravir Potassium